PE20221463A1 - Celula vector adyuvante artificial con contenido de ny-eso-1 para usar en el tratamiento del cancer - Google Patents

Celula vector adyuvante artificial con contenido de ny-eso-1 para usar en el tratamiento del cancer

Info

Publication number
PE20221463A1
PE20221463A1 PE2022000986A PE2022000986A PE20221463A1 PE 20221463 A1 PE20221463 A1 PE 20221463A1 PE 2022000986 A PE2022000986 A PE 2022000986A PE 2022000986 A PE2022000986 A PE 2022000986A PE 20221463 A1 PE20221463 A1 PE 20221463A1
Authority
PE
Peru
Prior art keywords
eso
cancer
treatment
fragment
polynucleotide encoding
Prior art date
Application number
PE2022000986A
Other languages
English (en)
Inventor
Ayaka AKIBA
Tatsuya Okudaira
Yasuhide MASUHARA
Keisuke Ohsumi
Shinichiro Fujii
Original Assignee
Astellas Pharma Inc
Riken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Riken filed Critical Astellas Pharma Inc
Publication of PE20221463A1 publication Critical patent/PE20221463A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion se refiere a una celula vector adyuvante artificial (aAVC) que expresan de manera estable y elevada NY-ESO-1 (celulas escamosas esofagicas de New York 1) o un fragmento de esta, como antigeno de cancer. Una celula de origen humano que comprende un polinucleotido que codifica CD1d y un polinucleotido que codifica NY-ESO-1 o un fragmento de esta, donde el polinucleotido que codifica NY-ESO-1 o un fragmento de esta esta operativamente ligado a un promotor inducible. Tambien refiere a una composicion farmaceutica que comprende dicha celula para el tratamiento de pacientes con cancer que expresa NY-ESO-1.
PE2022000986A 2019-12-02 2020-12-01 Celula vector adyuvante artificial con contenido de ny-eso-1 para usar en el tratamiento del cancer PE20221463A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019217704 2019-12-02
PCT/JP2020/044586 WO2021112055A1 (ja) 2019-12-02 2020-12-01 がんの処置に用いるｎｙ－ｅｓｏ－１含有人工アジュバントベクター細胞

Publications (1)

Publication Number Publication Date
PE20221463A1 true PE20221463A1 (es) 2022-09-21

Family

ID=76222293

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000986A PE20221463A1 (es) 2019-12-02 2020-12-01 Celula vector adyuvante artificial con contenido de ny-eso-1 para usar en el tratamiento del cancer

Country Status (20)

Country Link
US (2) US11672851B2 (es)
EP (1) EP4071240A4 (es)
JP (1) JPWO2021112055A1 (es)
KR (1) KR20220119030A (es)
CN (1) CN114787344A (es)
AR (1) AR120648A1 (es)
AU (1) AU2020394993A1 (es)
BR (1) BR112022010763A2 (es)
CA (1) CA3162277A1 (es)
CL (1) CL2022001459A1 (es)
CO (1) CO2022008738A2 (es)
CR (1) CR20220320A (es)
DO (1) DOP2022000108A (es)
EC (1) ECSP22049399A (es)
IL (1) IL293482A (es)
JO (1) JOP20220121A1 (es)
MX (1) MX2022006716A (es)
PE (1) PE20221463A1 (es)
TW (1) TW202134431A (es)
WO (1) WO2021112055A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130189302A1 (en) * 2006-02-22 2013-07-25 Riken Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5672647B2 (ja) * 2006-02-22 2015-02-18 独立行政法人理化学研究所 ＣＤ１ｄリガンドをパルスした、標的抗原及びＣＤ１ｄの共発現細胞による免疫療法
US20130189302A1 (en) * 2006-02-22 2013-07-25 Riken Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen
JP2007261876A (ja) 2006-03-28 2007-10-11 Tdk Corp 誘電体粒子、誘電体磁器組成物およびその製造方法
US9163088B2 (en) * 2006-10-27 2015-10-20 Temple University Tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera
US9603922B2 (en) * 2007-02-21 2017-03-28 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CD1d molecules
US20110280895A1 (en) * 2008-11-28 2011-11-17 Riken IMMUNOTHERAPEUTIC METHOD USING ALLO-CELLS WHICH CO-EXPRESS CD1d AND TARGET ANTIGEN
KR101194265B1 (ko) 2008-12-01 2012-10-29 주식회사 한국인삼공사 해양심층수를 이용하여 인삼 또는 홍삼 농축액의 고미 제거방법
EP2550157A2 (en) 2010-03-25 2013-01-30 3M Innovative Properties Company Composite layer
CA2843386A1 (en) 2011-07-29 2013-02-07 Riken Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct
US10316332B2 (en) * 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
EP3326641B1 (en) * 2015-04-22 2019-06-26 CureVac AG Rna containing composition for treatment of tumor diseases
US20170216370A1 (en) 2015-07-31 2017-08-03 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
CA2996535A1 (en) 2015-07-31 2017-02-09 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
US20200085944A1 (en) * 2017-03-17 2020-03-19 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy

Also Published As

Publication number Publication date
MX2022006716A (es) 2022-09-12
CN114787344A (zh) 2022-07-22
US11672851B2 (en) 2023-06-13
DOP2022000108A (es) 2022-10-31
US20230000965A1 (en) 2023-01-05
AR120648A1 (es) 2022-03-09
CA3162277A1 (en) 2021-06-10
KR20220119030A (ko) 2022-08-26
TW202134431A (zh) 2021-09-16
IL293482A (en) 2022-08-01
EP4071240A4 (en) 2024-01-17
WO2021112055A1 (ja) 2021-06-10
JPWO2021112055A1 (es) 2021-06-10
CR20220320A (es) 2022-11-03
US20230330200A1 (en) 2023-10-19
BR112022010763A2 (pt) 2022-08-23
JOP20220121A1 (ar) 2023-01-30
EP4071240A1 (en) 2022-10-12
CO2022008738A2 (es) 2022-07-19
CL2022001459A1 (es) 2023-02-24
AU2020394993A1 (en) 2022-06-09
ECSP22049399A (es) 2022-08-31

Similar Documents

Publication Publication Date Title
BR112017001183A2 (pt) tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
PE20210488A1 (es) Anticuerpos especificos para gucy2c y sus usos
BR112017000939A2 (pt) tratamento de câncer usando um receptor antigênico quimérico de cll-1
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
BR112017001242A2 (pt) tratamento de câncer usando um receptor antigênico quimérico a cd33
BR112017003104A2 (pt) tratamento de câncer usando um receptor antigênico quimérico anti-cd123
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
AR101740A1 (es) Terapia de combinación y composiciones
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
PE20151434A1 (es) Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo
CO2023013465A2 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
CO7000770A2 (es) Terapia combinada para el tratamiento del cáncer de ovario
CO2019003865A2 (es) Proteína terapéutica
AR120057A1 (es) Composiciones neoantigénicas y usos de estas
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
EA201992562A1 (ru) Пептиды для лечения сахарного диабета
PE20221463A1 (es) Celula vector adyuvante artificial con contenido de ny-eso-1 para usar en el tratamiento del cancer
CO2020004244A2 (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2021005386A (es) Fragmentos de peptidos para tratamiento de diabetes.
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.
CL2023000492A1 (es) Vector de poxviridae recombinante que expresa moléculas coestimuladoras
EA202100145A1 (ru) Применение гуанабенза